(NASDAQ: MREO) Mereo Biopharma Group's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.8%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.78%.
Mereo Biopharma Group's earnings in 2026 is -$28,099,000.On average, 8 Wall Street analysts forecast MREO's earnings for 2026 to be -$28,504,839, with the lowest MREO earnings forecast at -$39,124,288, and the highest MREO earnings forecast at -$25,151,328. On average, 8 Wall Street analysts forecast MREO's earnings for 2027 to be -$36,649,078, with the lowest MREO earnings forecast at -$54,774,004, and the highest MREO earnings forecast at -$25,151,328.
In 2028, MREO is forecast to generate -$65,153,917 in earnings, with the lowest earnings forecast at -$62,598,861 and the highest earnings forecast at -$67,070,209.